Cardiology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
J Cardiovasc Electrophysiol. 2010 Apr;21(4):473-86. doi: 10.1111/j.1540-8167.2009.01694.x. Epub 2010 Feb 1.
Arrhythmogenic right ventricular dysplasia (ARVD) is a genetically determined myocardial disease characterized by fibrofatty replacement of the right ventricular wall. Ventricular tachyarrhythmias can be seen in the early stages of the disease, which is one of the most important causes of sudden death in young healthy individuals. Radiofrequency (RF) catheter ablation is an option for the treatment of medically refractory ventricular arrhythmias and it has shown to successfully abolish recurrent ventricular tachycardias (VT) as well as reduce the frequency in defibrillator therapies. However, variable acute and long-term success rates have been reported. The current mapping and ablation techniques include activation and entrainment mapping during tolerated VT and substrate ablation using 3-dimensional electroanatomic mapping systems. This article aims at providing a comprehensive review of RF catheter ablation of ventricular arrhythmias in the context of ARVD.
致心律失常性右室心肌病（ARVD）是一种遗传性心肌疾病，其特征为右心室壁的纤维脂肪替代。在疾病的早期阶段可出现室性心律失常，这是年轻健康个体发生心源性猝死的最重要原因之一。射频（RF）导管消融是治疗药物难治性室性心律失常的一种选择，已证明其可成功消除复发性室性心动过速（VT），并减少除颤器治疗的频率。然而，已有报道显示其存在可变的急性和长期成功率。目前的标测和消融技术包括在可耐受的 VT 期间进行激活和拖带标测，以及使用三维电生理标测系统进行基质消融。本文旨在提供 RF 导管消融治疗 ARVD 中室性心律失常的综合综述。
